Oncotarget · 2016 · 69 citations · 28 references
MedicineMolecular MedicineOncologyMolecular DiagnosticsMolecular OncologyOncogenesCancer BiomarkersCancer GenomicsCirculating Tumor Dna AnalysisMolecular Tumor ProfilingNext-generation Sequencing In OncologyPancreatic CancerCirculating Cell-free Dna AnalysisCirculating Tumor BiomarkersCirculating Tumor Dna DetectionCirculating Tumor Dna SequencingCirculating Tumor Dna TestingClinical Next-generation SequencingNext-generation Sequencing-based DetectionTumor Mutation Detection
// Michael J. Pishvaian 1,2,* , R. Joseph Bender 1,* , Lynn M. Matrisian 3 , Lola Rahib 3 , Andrew Hendifar 4 , William A. Hoos 3 , Sam Mikhail 5 , Vincent Chung 6 , Vincent Picozzi 7 , Craig Heartwell 1 , Kimberly Mason 1 , Katelyn Varieur 1 , Metasebia Aberra 1 , Subha Madhavan 1,2 , Emanuel Petricoin III 1 and Jonathan R. Brody 1,8 1 Perthera, Inc, McLean, VA, USA 2 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA 3 The Pancreatic Cancer Action Network, Manhattan Beach, CA, USA 4 Cedars-Sinai Medical Center, Los Angeles, CA, USA 5 Ohio State University, Columbus, OH, USA 6 City of Hope Cancer Center, Duarte, CA, USA 7 Virginia Mason Medical Center, Seattle, WA, USA 8 Jefferson Pancreatic, and Related Cancer Center, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA * These authors have contributed equally to this work Correspondence to: Jonathan R. Brody, email: // Keywords : cfDNA, pancreatic cancer, blood-based NGS Received : June 15, 2016 Accepted : September 25, 2016 Published : November 08, 2016 Abstract Recent improvements in next-generation sequencing (NGS) technology have enabled detection of biomarkers in cell-free DNA in blood and may ultimately replace invasive tissue biopsies. However, a better understanding of the performance of blood-based NGS assays is needed prior to routine clinical use. As part of an IRB-approved molecular profiling registry trial of pancreatic ductal adenocarcinoma (PDA) patients, we facilitated blood-based NGS testing of 34 patients from multiple community-based and high-volume academic oncology practices. 23 of these patients also underwent traditional tumor tissue-based NGS testing. cfDNA was not detected in 9/34 (26%) patients. Overall concordance between blood and tumor tissue NGS assays was low, with only 25% sensitivity of blood-based NGS for tumor tissue NGS. Mutations in KRAS, the major PDA oncogene, were only detected in 10/34 (29%) blood samples, compared to 20/23 (87%) tumor tissue biopsies. The presence of mutations in circulating DNA was associated with reduced overall survival (54% in mutation-positive versus 90% in mutation-negative). Our results suggest that in the setting of previously treated, advanced PDA, liquid biopsies are not yet an adequate substitute for tissue biopsies. Further refinement in defining the optimal patient population and timing of blood sampling may improve the value of a blood-based test.
28
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text
Medicine, Oncology, Pharmacology +13
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.7K citations
Medicine, Oncology, Pharmacology +13
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda, Mark Sausen, Rebecca Leary et al. · Science Translational Medicine · 2014 · 5.1K citations · Full text
Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4.1K citations
Medicine, Oncology, Pharmacology +10